focus
Previous article:
Moonlake's readout produced a cash windfall. Risks remain
Next article: Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal
Next article: Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal
entertainment
hotspot
-
Disclosing genetic information: not as worrisome as once feared
2025-08-23 03:41 -
Immunocompromised patients offer clues on chronic Covid
2025-08-23 03:39 -
What is the Wagner Group? The 'brutal' Russian military unit in Ukraine
2025-08-23 02:42 -
There's an unseen cost to disruptive road
2025-08-23 02:28 -
Future doctors need a strong humanities education
2025-08-23 01:16 -
Flu vaccine reformulation won't be easy, manufacturers warn
2025-08-23 01:02